Second Generation Oral Ganaxolone is under clinical development by Marinus Pharmaceuticals and currently in Phase II for Lennox-Gastaut Syndrome. According to GlobalData, Phase II drugs for Lennox-Gastaut Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Second Generation Oral Ganaxolone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Second Generation Oral Ganaxolone overview
Ganaxolone is under development for the treatment of Lennox-Gastaut syndrome. It is a second generation ganaxolone. The drug candidate is administered by oral route as suspension.
Marinus Pharmaceuticals overview
Marinus Pharmaceuticals is a biopharmaceutical company. It discovers, develops and commercializes therapies for the treatment of rare genetic epilepsies and other seizure disorders. The company’s product includes Ganaxolone, a novel gamma-aminobutyric acid (GABA) receptor modulator, which is developed in intravenous (IV) and oral formulations. Marinus Pharmaceuticals carries out research and development, educational grants, and other services. It markets products under the brand name Ztalmy. The company’s product help in the treatment of acute and chronic care settings, seizure disorders, rare epilepsies, pediatric epilepsies, brain disorders, and other disorders. It serves healthcare providers, caregivers, healthcare professionals, and others. Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania, the US.
For a complete picture of Second Generation Oral Ganaxolone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
